Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dato-DXd plus durvalumab in early-stage TNBC or HR-low/HER2-negative breast cancer
NCT06112379Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Nov 2023
- Primary completion
- Nov 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 26
01
Overview
A Phase 3 trial of datopotamab deruxtecan in breast cancer, sponsored by AstraZeneca. Started Nov 2023; status: active, not recruiting.
02
Drugs
datopotamab deruxtecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06112379.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06112379.